TY - JOUR
T1 - Patient-reported experience with the use of Mepitel Film for prevention of acute radiation dermatitis in breast cancer
AU - Gojsevic, Milena
AU - Kennedy, Samantha
AU - Rajeswaran, Thenugaa
AU - Herst, Patries
AU - Safavi, Amir H.
AU - Corbin, Kimberly
AU - Hill, Rosemary
AU - Tran, William
AU - Carothers, Katherine
AU - Gallant, François
AU - Trombetta, Mark
AU - Arscott, William T.
AU - Shariati, Saba
AU - Lam, Jacqueline
AU - Akkila, Shereen
AU - Behroozian, Tara
AU - Zhang, Elwyn
AU - Karam, Irene
AU - Chow, Edward
N1 - Publisher Copyright:
© 2024, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2024/1
Y1 - 2024/1
N2 - Background and purpose: Mepitel Film (MF) has been demonstrated to reduce the severity of radiation dermatitis (RD) in patients receiving breast cancer radiotherapy (RT). The objective of this study was to characterize patient-reported experience with MF use, including its impact on daily activities and wellbeing. Materials and methods: This single-institution study analyzed anonymized responses to a questionnaire completed by patients who used MF for the prevention of RD during breast cancer RT. Results: Of the 254 patients contacted, 192 patients completed the survey. Most patients disagreed or strongly disagreed that MF limited their ability to perform their daily activities, including household chores (88%, n = 169/191), their ability to work (83%, n = 157/189), or their ability to sleep (85%, n = 163/191). Furthermore, patients agreed or strongly agreed MF was comfortable on their skin (67%, n = 126/189) and protected their skin from rubbing against clothing (86%, n = 161/188). Some patients agreed or strongly agreed that MF affected their ability to shower (31%, n = 50/162), wear bras (28%, n = 51/185), and impacted their level of pruritus (35%, n = 67/189). However, most patients agreed or strongly agreed that their overall experience with MF was positive (92%, n = 173/189) and would recommend MF to a friend undergoing breast cancer RT (88%, n = 166/188). Conclusion: MF use is associated with positive patient-reported experience during breast RT with minimal impact on daily activities.
AB - Background and purpose: Mepitel Film (MF) has been demonstrated to reduce the severity of radiation dermatitis (RD) in patients receiving breast cancer radiotherapy (RT). The objective of this study was to characterize patient-reported experience with MF use, including its impact on daily activities and wellbeing. Materials and methods: This single-institution study analyzed anonymized responses to a questionnaire completed by patients who used MF for the prevention of RD during breast cancer RT. Results: Of the 254 patients contacted, 192 patients completed the survey. Most patients disagreed or strongly disagreed that MF limited their ability to perform their daily activities, including household chores (88%, n = 169/191), their ability to work (83%, n = 157/189), or their ability to sleep (85%, n = 163/191). Furthermore, patients agreed or strongly agreed MF was comfortable on their skin (67%, n = 126/189) and protected their skin from rubbing against clothing (86%, n = 161/188). Some patients agreed or strongly agreed that MF affected their ability to shower (31%, n = 50/162), wear bras (28%, n = 51/185), and impacted their level of pruritus (35%, n = 67/189). However, most patients agreed or strongly agreed that their overall experience with MF was positive (92%, n = 173/189) and would recommend MF to a friend undergoing breast cancer RT (88%, n = 166/188). Conclusion: MF use is associated with positive patient-reported experience during breast RT with minimal impact on daily activities.
KW - Mepitel Film
KW - Patient satisfaction surveys
KW - Radiation dermatitis
UR - http://www.scopus.com/inward/record.url?scp=85181520525&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85181520525&partnerID=8YFLogxK
U2 - 10.1007/s00520-023-08302-4
DO - 10.1007/s00520-023-08302-4
M3 - Article
C2 - 38190084
AN - SCOPUS:85181520525
SN - 0941-4355
VL - 32
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 1
M1 - 89
ER -